small molecule

ZOLYMBUS

BIMATOPROST

Loss of exclusivityJune 2036latest FDA-listed patent expiry

CompanyThea →View the full company profile on CliffBio

Drug detail

Brand name	ZOLYMBUS
Active ingredient	BIMATOPROST
Strength	0.01%
Dosage form	GEL
Route	OPHTHALMIC
Modality	Small molecule
FDA approval	September 2025
Marketing status	RX

Listed patents

Patent	Expires	Type
10314780	June 2036	product

Regulatory exclusivity

Code	Expires
NDF	September 2028

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Thea